Mahler S J, De Villez R L, Pulitzer D R
Division of Dermatology, University of Texas Health Science Center, San Antonio 78284-7876.
J Am Acad Dermatol. 1993 Aug;29(2 Pt 1):206-9. doi: 10.1016/0190-9622(93)70169-t.
Interleukin 4 is one of many cytokines under investigation about its possible role in the pathogenesis and treatment of disease. Transient acantholytic dermatosis is of uncertain origin. It has not previously been linked to drug ingestion and is generally not believed to have an immunologic basis.
Our purpose was to describe the clinical characteristics and histologic features of a cutaneous eruption caused by interleukin 4.
Three patients in whom an eruption developed after they received intravenous recombinant human interleukin 4 were examined and biopsy specimens were evaluated.
These patients had a pruritic papulovesicular eruption that was consistent, both clinically and histologically, with transient acantholytic dermatosis. None of the other conditions believed to precipitate transient acantholytic dermatosis was present in our patients.
This is the first report of a cutaneous side effect of interleukin 4. This may be antibody-mediated or related to increased production of tissue-type plasminogen activator.
白细胞介素4是众多正在研究其在疾病发病机制和治疗中可能作用的细胞因子之一。暂时性棘层松解性皮病的病因不明。此前它未被认为与药物摄入有关，且一般不认为有免疫基础。
我们的目的是描述由白细胞介素4引起的皮肤疹的临床特征和组织学特征。
对3例接受静脉注射重组人白细胞介素4后出现皮疹的患者进行检查，并对活检标本进行评估。
这些患者出现瘙痒性丘疹水疱疹，在临床和组织学上均与暂时性棘层松解性皮病相符。我们的患者不存在其他被认为可引发暂时性棘层松解性皮病的情况。
这是白细胞介素4皮肤副作用的首例报告。这可能是抗体介导的，或与组织型纤溶酶原激活物产生增加有关。
